SCHEMBL55563

SCHEMBL55563

Clc1nc(Cl)c2sccc2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.58
ADORA1 P30542 6/20 0.58
AXL P30530 1/20 0.55
MKNK1 Q9BUB5 1/20 0.55
MKNK2 Q9HBH9 1/20 0.55
TUBB4A P04350 2/20 0.46
TUBB P07437 2/20 0.46
TUBA3C P0DPH7 2/20 0.46
TUBA1B P68363 2/20 0.46
TUBA4A P68366 2/20 0.46
TUBB4B P68371 2/20 0.46
TUBB3 Q13509 2/20 0.46
TUBB2A Q13885 2/20 0.46
TUBB8 Q3ZCM7 2/20 0.46
TUBA3E Q6PEY2 2/20 0.46
TUBA1A Q71U36 2/20 0.46
TUBA1C Q9BQE3 2/20 0.46
TUBB6 Q9BUF5 2/20 0.46
TUBB2B Q9BVA1 2/20 0.46
TUBB1 Q9H4B7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31462939 1.00 ADORA2A (0.58) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL9383494 0.81 ADORA2A (0.53) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL61922 0.81 ADORA2A (0.53) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL13236422 0.81 ADORA2A (0.53) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL1367259 0.78 AXL (0.52) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL2876033 0.78 AXL (0.52) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL3679866 0.78 ADORA2A (0.50) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL24174509 0.77 HTT (0.61) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL2533678 0.77 TUBB4A (0.61) ADORA2AADORA1AXLMKNK1MKNK2
SCHEMBL20609567 0.77 ADORA2A (0.49) ADORA2AADORA1AXLMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1007 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118388506-A Pyrimidothiophene compound of 3-aminothiophene fragment, preparation method and application thereof 贵州大学 2024-07-26 CN claimed
CN-116640095-A Diaryl amine derivative containing aliphatic carboxyl and preparation method and application thereof 山东大学 2023-08-25 CN claimed
CN-112920199-A Piperazinone substituent or derivative thereof, and preparation method, application and pharmaceutical composition thereof 四川大学 2021-06-08 CN claimed
CN-111943959-A Synthetic method of JAK inhibitor 上海再极医药科技有限公司 2020-11-17 CN claimed
CN-108440559-B Diaryl thienopyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof 山东大学 2020-06-16 CN claimed
EP-2786998-B1 THIENYL [3, 2-D]PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2018-07-25 EP claimed
EP-2214675-B1 PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS GENENTECH INC (US) 2013-11-20 EP claimed
US-8354528-B2 Process for making thienopyrimidine compounds GENENTECH, INC. (US) 2013-01-15 US claimed
US-20100292468-A1 PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS GENETECH, INC 2010-11-18 US claimed
EP-2214675-A1 PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS Genentech, Inc. (US) 2010-08-11 EP claimed
WO-2009055730-A1 PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS GENENTECH, INC. (US) 2009-04-30 WO claimed
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2026-05-26 US disclosed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 US disclosed
EP-4709480-A1 5,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS Amgen Inc. (US) 2026-03-18 EP disclosed
US-5187168-A Hypotensive agents AMERICAN HOME PRODUCTS CORPORATION (US) 1993-02-16 US disclosed
EP-0404356-A1 Substituted thienopyrimidine derivatives, their preparation, pharmaceutical compositions and medical use SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1990-12-27 EP disclosed
EP-0008408-B1 1,2,3,5-TETRAHYDROIMIDAZOTHIENOPYRIMIDIN-2-ONES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS DAIICHI SEIYAKU CO., LTD. (JP) 1981-12-09 EP disclosed
US-4284773-A ANTICOAGULANTS DAIICHI SEIYAKU CO., LTD. (JP) 1981-08-18 US disclosed
EP-0008408-A1 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones, a process for their preparation and pharmaceutical compositions DAIICHI SEIYAKU CO., LTD. (JP) 1980-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292468-A1 PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS PIK3CA, PIK3CD, PIK3CB ADORA2A 1376/4885ADORA1 1397/4885AXL 891/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B ADORA2A 847/4885ADORA1 919/4885AXL 1446/4885
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy OGFR, CBR3, CBR1 ADORA2A 3749/4885ADORA1 1138/4885AXL 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.